Metacine is a San Diego-based company that specializes in the research and development of drugs for liver and gastrointestinal (GI) diseases, such as nonalcoholic steatohepatitis (NASH), irritable bowel syndrome with diarrhea (IBS-D), and inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn’s disease.
The company has multiple programs running for the research and development of its products. Its FXR
agonist program is designed for NASH and IBD and is in the Phase 2 and Phase 1 of clinical trials for each respective disease. The SSAO/VAP-1 Inhibitor program is an inflammatory target and is in the pre-clinical stage of development. Its HSD17B13 inhibitor is also for NASH and is in the lead optimizations stage.
The drug from its FXR agonist program is called MET409 and has seen success when it was administered in different dosages along with a placebo group. When the drug was dosed at 80 milligrams to patients, researchers saw a 55% reduction in relative mean liver fat content in the patients.
Preston Klassen, M.D., MHS
President and CEO
Metacrine Demonstrates Best-in-Class FXR Drug Program with Positive Clinical Results in NASH Patients
January 22, 2020
Metacrine Secures $50 Million Growth Capital Facility from K2 HealthVentures
September 18, 2019